Reducing acid exposure is the key to improving chronic laryngitis caused by reflux. When stomach acid refluxes up to the larynx, it irritates the vocal cords and surrounding tissues, leading to persistent hoarseness, throat clearing, and irritation. Proton pump inhibitors, such as omeprazole, block the final step of acid production in the stomach, decreasing overall acid in the refluxate. With less acid contact, the laryngeal mucosa can heal, and symptoms improve. This directly targets the underlying cause rather than trying to treat infection or allergic inflammation. Antibiotics would not help because there is no bacterial infection. Antihistamines address allergy symptoms and won’t resolve acid-induced irritation. Steroids don’t treat the reflux itself and aren’t the standard approach for reflux-related laryngitis.

Red flags in tinnitus evaluation are features that point to a potentially serious, non-benign cause. The finding described—pulsatile, unilateral tinnitus with asymmetric hearing loss—strongly suggests a pathologic process such as a vascular abnormality or a retrocochlear lesion. Pulsatile tinnitus means the sound aligns with the heartbeat, which often comes from abnormal blood flow in nearby vessels or a vascular tumor. When it’s confined to one ear and accompanied by asymmetric hearing loss, it raises concern for conditions like a glomus tumor, carotid or dural vascular anomaly, or a vestibular schwannoma, all of which can require imaging and specialist assessment. Most tinnitus seen in primary care is nonpulsatile, bilateral, and associated with symmetric hearing loss from noise exposure or age-related changes, which is generally not a red flag. Tinnitus that improves with noise exposure or lasts only a short time without focal deficits is less concerning for serious pathology. Because the pulsatile, unilateral pattern with asymmetric hearing loss points toward a possible structural or vascular problem, this finding warrants appropriate workup, including imaging (such as MRI with contrast and possibly vascular imaging) and referral for further evaluation.

QT prolongation sets the stage for a specific dangerous ventricular tachyarrhythmia: Torsades de Pointes. When the heart’s repolarization is unusually extended, early afterdepolarizations can trigger a rapid, twisting ventricular rhythm. This arrhythmia is often pause- or bradycardia-dependent and can be precipitated by factors common in people with prior cardiac history, such as electrolyte abnormalities, certain drugs, or underlying structural heart disease. On ECG, Torsades de Pointes appears as a polymorphic VT with QRS complexes that twist around the baseline, a distinct pattern that distinguishes it from other rhythms. If not promptly treated, it can degenerate into ventricular fibrillation. The other options don’t have the same direct link to QT duration: a general ventricular tachycardia can arise from various substrates, atrial fibrillation is an atrial rhythm disturbance, and sinus bradycardia is simply a slow heart rate that isn’t itself caused by QT length.

As people age, large arteries become stiffer due to structural changes in the vessel wall. This arterial stiffening reduces the aorta’s ability to recoil during systole, so systolic blood pressure tends to rise. Diastolic pressure tends to stay the same or decline a bit, which widens the gap between systolic and diastolic pressures. That widening is the pulse pressure, and it becomes more pronounced in the elderly. For example, going from about 120/80 to something like 150/85 illustrates the increased pulse pressure. This arterial stiffness-driven change is the classic, expected physiologic pattern in aging. While other age-related changes exist (such as some reduction in heart rate variability), the hallmark finding is a wider pulse pressure.

Blocking the renin-angiotensin-aldosterone system with ACE inhibitors reduces mortality in heart failure with reduced ejection fraction by slowing maladaptive remodeling, lowering afterload, and dampening harmful neurohormonal activation. Large randomized trials like CONSENSUS and SOLVD showed clear survival benefits and fewer hospitalizations with ACE inhibitors in patients with reduced EF. Diuretics help symptoms and fluid management but don’t improve long-term survival. Calcium channel blockers generally do not improve mortality in HFrEF and can be harmful in some cases, while nitrates (without hydralazine) lack broad mortality benefit though the hydralazine–nitrate combo has shown benefit in specific subgroups. Thus, ACE inhibitors have the strongest, widely demonstrated mortality benefit in this population.